Hypertrophic Cardiomyopathy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years; 2.Clinically confirmed HCM; 3.Resting left ventricular outflow tract gradient < 30 mmHg; 4.Signed written informed consent.
Exclusion criteria
Exclusion criteria: 1.Known infiltrative or storage disorders causing cardiac hypertrophy or mimicking HCM, such as Fabry disease, amyloidosis, or Noonan syndrome with left ventricular hypertrophy; 2.History of presyncope or syncope; 3.Concurrent acute coronary syndrome; 4.Symptomatic malignant arrhythmias; 5.Refractory hypertension (resting systolic BP > 180 mmHg or diastolic BP > 110 mmHg); 6.Refractory tachycardia or bradycardia; 7.Decompensated symptomatic heart failure; 8.Symptomatic severe aortic stenosis (mean transvalvular gradient = 20 mmHg); 9.Acute pulmonary embolism or deep vein thrombosis; 10.Acute myocarditis/pericarditis; 11.Acute aortic dissection; 12.Other conditions judged by the investigator to preclude the performance of provocative maneuvers; 13.Current or prior treatment with a selective cardiac myosin inhibitor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular outflow tract pressure gradient;Detection rate of occult obstruction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events;Increments of LVOTG induced by different excitation tests;The diagnostic efficiency of various provocation tests in HCM patients stratified based on cardiac MRI subtypes and NT-proBNP levels; | — |
Countries
China
Contacts
The First Affiliated Hospital of the University of Science and Technology of China